文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

基孔肯雅热疫苗系统综述:Ixchiq与Vimkunya的免疫原性、耐受性与安全性

Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya.
PubMed 文献 · Vaccine · 2026-01-20

德国常设疫苗接种委员会与德国热带医学学会工作组系统综述了两种新获批基孔肯雅热疫苗的免疫原性、耐受性与安全性。因无临床效力数据,以血清阳性率作为保护替代指标:Ixchiq接种4周后血清保护率>98%;Vimkunya接种3周后12-59岁>97%、≥65岁>87%。两疫苗安全性可接受,但Ixchiq在老年患者中上市后监测显示严重不良事件风险较高。

要点

  • 两种疫苗均以血清保护率作为保护替代指标,无临床效力数据。
  • Ixchiq接种4周后血清保护率>98%,Vimkunya接种3周后12-59岁>97%。
  • Vimkunya在≥65岁人群接种3周后血清保护率>87%。

核心结论

  • 除防蚊和媒介控制外,两种基于血清保护替代指标显示良好效力的疫苗可用于预防基孔肯雅热。
  • 两疫苗耐受性可接受,但需基于各人群上市后监测数据持续评估安全性。

研究设计与样本

  • 德国常设疫苗接种委员会(STIKO)与德国热带医学、旅行医学与全球健康学会(DTG)工作组开展的系统综述。
  • 检索Embase和PubMed(OVID),按预设PICO标准纳入安慰剂对照随机对照试验、队列研究和病例对照研究。
  • 使用RoB 2工具评估偏倚风险,并研究上市后安全性数据。

主要发现

  • 无临床效力数据可用,以超过预设阈值的血清阳性率作为保护替代指标。
  • Ixchiq接种4周后血清保护率>98%。
  • Vimkunya接种3周后12-59岁人群血清保护率>97%,≥65岁人群>87%。
  • 关键研究中两疫苗均显示可接受的安全性特征。
  • 上市后安全性数据显示Ixchiq在老年患者中严重不良事件风险较高。

关键数值与推荐

  • Ixchiq:接种4周后血清保护率>98%。
  • Vimkunya:接种3周后12-59岁血清保护率>97%,≥65岁>87%。

临床怎么用

  • 在防蚊和媒介控制基础上,可考虑使用Ixchiq或Vimkunya预防基孔肯雅热。
  • 对老年患者使用Ixchiq时应关注上市后监测提示的严重不良事件风险。
  • 持续通过上市后监测评估疫苗在各自人群中的安全性。

局限性

  • 无临床效力数据,仅以血清保护率作为替代指标。
  • 需进一步上市后监测数据持续评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infections with the chikungunya virus are increasingly reported due to many reasons including climate change. Two vaccines against chikungunya have recently been approved in Europe, the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. However, no systematic review of phase 3 clinical trial data has been published that summarizes the currently available evidence on the immunogenicity, tolerability, and safety of these vaccines. Therefore, these data were systematically analyzed by a working group of the German Standing Committee on Vaccination (STIKO) and the German Society for Tropical Medicine, Travel Medicine and Global Health (DTG). METHODS: We conducted a systematic review of the immunogenicity, tolerability and safety of Ixchiq and Vimkunya using Embase and PubMed (OVID) according to predefined PICO criteria, including placebo-controlled randomized control trials, cohort, and case-control studies. Risk of bias (RoB) was assessed with the RoB 2-tool. Additionally, post-marketing safety data were studied. RESULTS: Clinical efficacy data were not available. Instead, seropositivity rates above a predefined threshold served as a surrogate of protection. Both vaccines demonstrated strong immunogenicity with seroprotection rates for Ixchiq of >98% after 4 weeks, and for Vimkunya after 3 weeks of >97% in 12-59-year-olds and > 87% in ≥65-year-olds. In the pivotal studies, both vaccines showed also an acceptable safety profile. Post-marketing safety data showed a higher risk for serious adverse events in elderly patients for Ixchiq. CONCLUSION: In addition to mosquito protection and vector control, two vaccines with a good efficacy profile based on the surrogate marker of seroprotection are now available to prevent chikungunya. While both vaccines showed acceptable tolerability, the safety of vaccines must be continuously assessed based on further data from post-marketing surveillance of the respective populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kling K, Falman A, Branke L, et al. Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. Vaccine. 2026. PMID: 41564838. doi:10.1016/j.vaccine.2026.128251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。